Response Genetics Launches New Test for Cancer Immunotherapy Drug Development
The Company Offers Access to a Comprehensive Panel of Biomarkers for Cancer
LOS ANGELES, June 16, 2014 (GLOBE NEWSWIRE) -- Response Genetics, Inc.
(Nasdaq:RGDX), a company focused on the development and sale of molecular
diagnostic tests that help guide cancer therapy selection, today announced the
availability of new testing capabilities to advance cancer immunotherapy
clinical development. The Immuno-Oncology assay, which runs on HTG Molecular's
Edge System, is designed to measure the RNA expression of 26 commonly
investigated immunotherapy related genes enabling screening for response to
immunoregulatory pathways. The Iummo-Oncology test will be made available to
all of Response Genetics' existing biopharmaceutical partners, and new
potential partners, to aid in development of biomarker driven cancer
immunotherapy clinical trials.
"As the field of cancer immunotherapy continues to expand with potential
immunotherapeutic targets in a broad range of malignancies, we are pleased to
add immunotherapy testing to the portfolio of services we offer to our
biopharma clients," said Thomas A. Bologna, Chairman and Chief Executive
Officer of Response Genetics. "Regulation of the immune system is the key to
several therapeutic approaches for cancer treatment. A number of clinical
development programs being pioneered by large pharma are focused on signaling
pathways like PD-1, PD-L1, OX-40, LAG3 and CTLA4 with the goal of enabling the
immune system to attack cancer cells. The new assay covers these pathways as
well as numerous other targets."
Mr. Bologna added, "As evidenced at the recent annual meeting of the American
Society of Clinical Oncology, the characterization of biomarkers of response
to immunotherapeutic agents is focused on the expression levels of the
relevant receptors and ligands.Response Genetics was among the first
commercial organizations to harness the power of mRNA expression profiling as
a means to guide cancer therapy selection.The addition of the Immuno-Oncology
assay allows our pharma partners to further leverage our expertise in
RNA-based testing to shed light on potential biomarkers that identify patients
likely to respond to this new class of therapies."
About Response Genetics, Inc.
Response Genetics, Inc. (the "Company") is a CLIA-certified clinical
laboratory focused on the development and sale of molecular diagnostic testing
services for cancer.The Company's technologies enable extraction and analysis
of genetic information derived from tumor cells stored as formalin-fixed and
paraffin-embedded specimens.The Company's principal customers include
oncologists and pathologists.In addition to diagnostic testing services, the
Company generates revenue from the sale of its proprietary analytical
pharmacogenomic testing services of clinical trial specimens to the
pharmaceutical industry.The Company's headquarters is located in Los Angeles,
California.For more information, please visit www.responsegenetics.com.
Forward-Looking Statement Notice
Except for the historical information contained herein, this press release and
the statements of representatives of the Company related thereto contain or
may contain, among other things, certain forward-looking statements, within
the meaning of the Private Securities Litigation Reform Act of 1995.
Such forward-looking statements involve significant risks and
uncertainties.Such statements may include, without limitation, statements
with respect to the Company's plans, objectives, projections, expectations and
intentions, such as the ability of the Company, to provide clinical testing
services to the medical community, to continue to strengthen and expand its
sales force, to continue to build its digital pathology initiative, to attract
and retain qualified management, to continue to strengthen marketing
capabilities, to expand the suite of ResponseDX^® products, to continue to
provide clinical trial support to pharmaceutical clients, to enter into new
collaborations with pharmaceutical clients, to enter into areas of companion
diagnostics, to continue to execute on its business strategy and operations,
to continue to analyze cancer samples and the potential for using the results
of this research to develop diagnostic tests for cancer, the usefulness of
genetic information to tailor treatment to patients, and other statements
identified by words such as "project," "may," "could," "would," "should,"
"believe," "expect," "anticipate," "estimate," "intend," "plan" or similar
These statements are based upon the current beliefs and expectations of the
Company's management and are subject to significant risks and uncertainties,
including those detailed in the Company's filings with the Securities and
Exchange Commission.Actual results, including, without limitation, actual
sales results, if any, or the application of funds, may differ from those set
forth in the forward-looking statements.These forward-looking statements
involve certain risks and uncertainties that are subject to change based on
various factors (many of which are beyond the Company's control).The Company
undertakes no obligation to publicly update forward-looking statements,
whether because of new information, future events or otherwise, except as
required by law.
CONTACT: Investor Relations Contact:
Thomas A. Bologna
Chairman & Chief Executive Officer
Response Genetics Logo
Press spacebar to pause and continue. Press esc to stop.